This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Myriad Genetics Presents Favorable EMBRACA Trial Results
by Zacks Equity Research
Myriad Genetics (MYGN) adopts initiatives to boost uptake of BRACAnalysis CDx test.
Wright Medical (WMGI) Acquires IMASCAP SAS for $88.8 Million
by Zacks Equity Research
Wright Medical's (WMGI) acquisition of IMASCAP SAS will strengthen Extremities business.
Here's Why You Should Invest in Illumina (ILMN) Stock Now
by Zacks Equity Research
Illumina (ILMN) banks on product launches and international market prospects.
Myriad Genetics Rides on Solid Molecular Diagnostics Suite
by Zacks Equity Research
Myriad Genetics (MYGN) adopts initiatives to boost the Molecular Diagnostics portfolio.
Cooper Companies (COO) Tops Q4 Earnings & Revenue Estimates
by Zacks Equity Research
Cooper Companies (COO) continues to witness impressive results at the CooperVision business segment that delivered strong sales in Q4.
Genomic Health-Janssen Pharma Tie Up, GPS Test in Focus
by Zacks Equity Research
Genomic Health (GHDX) focuses on notable partnerships to promote its Oncotype DX Genomic Prostate Score (GPS) test.
Veeva Systems (VEEV) Beats on Earnings in Q3, Updates View
by Zacks Equity Research
Veeva Systems (VEEV) witnesses year-over-year growth in revenues on strength in subscription and professional services in Q3.
Ecolab Focuses on Pest Elimination, Acquires 3 Companies
by Zacks Equity Research
Ecolab (ECL) continues to focus on investment in key growth businesses and bolt-on acquisitions to gain market traction and boost profits and inorganic growth.
Boston Scientific (BSX) Shares Drop on LOTUS Relaunch Delay
by Zacks Equity Research
Boston Scientific (BSX) announces a delay in deadline for the commercial return of the LOTUS Edge Aortic Valve System in Europe. Following this news, share price declines.
BioTelemetry's (BEAT) Telcare Unit Collaborates With Onduo
by Zacks Equity Research
BioTelemetry (BEAT) progresses with deals to strengthen hold in the high-potential diabetes care market.